In short
There is currently 1 ongoing clinical trial investigating new treatment options for skin papilloma, also known as non-genital warts. This trial is being conducted in Belgium and focuses on testing treatments that use substances designed to help the body fight off the virus that causes warts.
Clinical trial locations
Study on the Effectiveness of Interferon Alfa, Interleukin-1, and Interleukin-2 in Treating Non-Genital Warts in Patients
This clinical trial is investigating whether two investigational treatments can effectively eliminate warts over a six-month period. The trial is taking place in Belgium and compares these treatments against a placebo to determine their effectiveness.
Who can participate:
- Patients must be 3 years old or older
- Both males and females can participate
- Patients must have common warts, plantar warts (warts on the soles of the feet), or flat warts
- Patients or their parents must be able to understand and follow the study requirements
- Signed informed consent is required from the patient or their parent
Who cannot participate:
- Individuals who have non-genital warts infection are excluded from this study
What the trial focuses on:
The main goal of this study is to see whether warts disappear completely by the end of the six-month treatment period. Participants will be randomly assigned to receive either 2LVERU, 2LVERU JUNIOR (designed for younger patients), or a placebo. The study is conducted in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the actual treatment or placebo during the trial.
The treatments being tested contain a combination of substances including interferon alfa, interleukin-1, interleukin-2, ribonucleic acid, and specific nucleic acids. These substances are designed to help the body's immune system fight off the virus that causes warts. The granules are taken by mouth and absorbed through the mucous membranes.
Throughout the study, participants will have regular check-ups at 4 months and 6 months to monitor whether the warts are disappearing and to track any potential side effects. Three months after treatment ends, there will be another follow-up visit to check if the warts have returned. The study also assesses pain levels and whether patients need to use pain relief medication.
Investigational drugs being tested:
The trial is testing 2LVERU JUNIOR for younger patients and 2LVERU for a broader range of patients. Both treatments aim to clear warts over the six-month treatment period by helping the body fight the virus responsible for wart growth.
Summary
Currently, there is one clinical trial available for patients with skin papilloma, located in Belgium. This trial is evaluating treatments that use immune-boosting substances to help the body eliminate warts naturally. The study is open to patients aged 3 years and older who have common, plantar, or flat warts. The focus is on determining whether these treatments can effectively make warts disappear and stay away after treatment ends, while carefully monitoring patient safety throughout the process.
